Abstract
Therapeutic antibodies have evolved into an important drug class and have achieved considerable success in combating cancers and autoimmune diseases. Although their potential in the treatment of viral infections has not yet been fully explored, recently established approaches have the potential to aid the development of HIV specific antibody therapies. Antibody engineering has led to improvements in antibody isolation and increases in antibody efficacy and potency. Strategies have been developed to tailor Fc recruitment of effector functions, and conjugation of monoclonals to toxins endows them with the ability to mediate destruction of specific target cells. These technical advances introduce the possibility of designing a therapy to target and clear cells infected with a broad range of HIV strains and recommend some hypothetical clinical settings in which advanced antibody therapeutics could be employed in prophylaxis or therapy for HIV infection.
Keywords: HIV, AIDS, therapeutic antibodies, passive immunization, infectious diseases, cancers, autoimmune diseases, viral infections, prophylaxis, neutralizing antibodies, anti-HIV drug, antiretroviral therapy, polyclonal immunoglobulin, respiratory syncytial virus, palivizumab, simian immunodeficiency virus, –, HIV chimera, Cell-mediated virus inhibition, cellular-phagocytosis, complement-mediated cytotoxicity, gp41, gp120, immunotoxin, CD4-MHC II, Ibalizumab, Human Genome Sciences, Natalizumab, Efalizumab, Half Life, Conjugating Antibodies, duocarmycin, calicheamicin, PEGylation, Camelids, Chondrichthyes
Current Pharmaceutical Design
Title: Therapeutic Antibodies in HIV Treatment - Classical Approaches to Novel Advances
Volume: 16 Issue: 33
Author(s): Irene A. Abela, Lucy Reynell and Alexandra Trkola
Affiliation:
Keywords: HIV, AIDS, therapeutic antibodies, passive immunization, infectious diseases, cancers, autoimmune diseases, viral infections, prophylaxis, neutralizing antibodies, anti-HIV drug, antiretroviral therapy, polyclonal immunoglobulin, respiratory syncytial virus, palivizumab, simian immunodeficiency virus, –, HIV chimera, Cell-mediated virus inhibition, cellular-phagocytosis, complement-mediated cytotoxicity, gp41, gp120, immunotoxin, CD4-MHC II, Ibalizumab, Human Genome Sciences, Natalizumab, Efalizumab, Half Life, Conjugating Antibodies, duocarmycin, calicheamicin, PEGylation, Camelids, Chondrichthyes
Abstract: Therapeutic antibodies have evolved into an important drug class and have achieved considerable success in combating cancers and autoimmune diseases. Although their potential in the treatment of viral infections has not yet been fully explored, recently established approaches have the potential to aid the development of HIV specific antibody therapies. Antibody engineering has led to improvements in antibody isolation and increases in antibody efficacy and potency. Strategies have been developed to tailor Fc recruitment of effector functions, and conjugation of monoclonals to toxins endows them with the ability to mediate destruction of specific target cells. These technical advances introduce the possibility of designing a therapy to target and clear cells infected with a broad range of HIV strains and recommend some hypothetical clinical settings in which advanced antibody therapeutics could be employed in prophylaxis or therapy for HIV infection.
Export Options
About this article
Cite this article as:
A. Abela Irene, Reynell Lucy and Trkola Alexandra, Therapeutic Antibodies in HIV Treatment - Classical Approaches to Novel Advances, Current Pharmaceutical Design 2010; 16 (33) . https://dx.doi.org/10.2174/138161210794079245
DOI https://dx.doi.org/10.2174/138161210794079245 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine The Neutrophil: An Underappreciated But Key Player in SLE Pathogenesis
Current Immunology Reviews (Discontinued) Potential Role of TRAIL in the Management of Autoimmune Diabetes Mellitus
Current Pharmaceutical Design DNA Vaccines: A Mini Review
Recent Patents on DNA & Gene Sequences Targeting of Th1-Associated Chemokine Receptors CXCR3 and CCR5 as Therapeutic Strategy for Inflammatory Diseases
Mini-Reviews in Medicinal Chemistry Fragment-Based Optimization of Small Molecule CXCL12 Inhibitors for Antagonizing the CXCL12/CXCR4 Interaction
Current Topics in Medicinal Chemistry Naturally Arising CD25+CD4+ Regulatory T Cells in Maintaining Immunologic Self-Tolerance and Preventing Autoimmune Disease
Current Molecular Medicine Regulation of Protective and Pathogenic Th17 Responses
Current Immunology Reviews (Discontinued) Use of Mesenchymal Stem Cells in Crohn's Disease and Perianal Fistulas: A Narrative Review
Current Stem Cell Research & Therapy Generation of Regulatory T Cells to Antigen Expressed in the Retina
Current Immunology Reviews (Discontinued) Autoimmunity-Inducing Metals (Hg, Au and Ag) Modulate Mast Cell Signaling, Function and Survival
Current Pharmaceutical Design JAK3 Inhibitors in Organ Transplantation and Autoimmune Disease
Recent Patents on Inflammation & Allergy Drug Discovery “Something is Wrong in the Ras Kingdom” - Evidence for the Involvement of p21Ras/MAP Kinase in Autoimmune Diseases
Current Rheumatology Reviews Erythropoietin Directly Affects Human Macrophage Functionality
Current Pharmaceutical Biotechnology Nucleic Acid Enzymes as a Novel Generation of Anti-gene Agents
Current Molecular Medicine Vasculitis Following Influenza Vaccination: A Review of the Literature
Current Rheumatology Reviews ImmunemiR - A Database of Prioritized Immune miRNA Disease Associations and its Interactome
MicroRNA Juvenile Systemic Lupus Erythematosus
Current Pediatric Reviews Sphingolipids in Cell Signaling: Their Function as Receptor Ligands, Second Messengers, and Raft Constituents
Current Immunology Reviews (Discontinued) HMGB-1 as a Target for Inflammation Controlling
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery